Posts tagged OTCQB:REPCF
RepliCel details go-forward strategy

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has formulated a strategic plan for 2017 through 2019 focused on maturing its assets through three distinct pillars.

Read More
RepliCel dermal injection device gets U.S. patent

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has received a key patent in the U.S. covering significant components of its novel, multi-needle dermal injection device. 

Read More
RepliCel posts positive RCS-01 interim results

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) reported statistically and clinically significant positive data from an interim analysis of its Phase I study evaluating RCS-01 for the treatment of aging and sun-damaged skin.

Read More
RepliCel hair loss trial meets primary endpoints

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has successfully completed its first-in-human clinical study of the company's autologous cell therapy for the treatment of androgenetic alopecia (pattern baldness).

Read More
RepliCel pursuing non-diluting grant funding

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP; FRA:P6P2) has retained The FreeMind Group, an international firm that assists life science organizations in securing non-dilutive funding from granting agencies and private foundations.

Read More
RepliCel in service partnerships for dermal injector

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP; FRA:P6P2) has signed agreements with two European firms to get the company's commercial-grade RCI-02 dermal injector prototypes manufactured and tested.

Read More
RepliCel receives two patents in Europe

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP) announced the granting of two patents in Europe related to its multi-needle dermal injection technologies. 

Read More